Citations

Clear

13603 citation(s) found for "_, _".

Advances in Kidney Transplant, Machine Perfusion, and Viability Markers
Ohara, Stephanie , Chávez‐Villa, Mariana , Mao, Shennen A. , Clendenon, Jacob , Heimbach, Julie, Ryan, Randi , Kodali, Lavanya, Nguyen, Michelle C., Nateras-Nunez, Rafael, Jadlowiec, Caroline C. , Jadlowiec, Caroline , Mao, Shennen A , Ohara, Stephanie Y , Ryan, Randi J. , Clendenon, Jacob N. , Chavez-Villa, Mariana , Heimbach, Julie, Kodali, Lavanya, Nguyen, Michelle C., Nateras-Nunez, Rafael

Mayo Clinic

Kidney and Dialysis | August 14, 2025 | Volume: 5 | Issue: 3 | Pages: 37

10.3390/kidneydial5030037 Get It

Despite improvements in kidney transplantation rates, the shortage of donor kidneys remains a critical issue, exacerbated by non-utilization of recovered kidneys due to quality concerns, necessitating advancements in perfusion methods to enhance graft outcomes and usage. Although static cold storage remains the default standard for kidney preservation, newer methods like hypothermic machine perfusion have shown improved outcomes, including reduced delayed graft function and better survival rates. Hypothermic oxygenated machine perfusion and normothermic machine perfusion offer some potential clinical benefits but studies to date have demonstrated mixed results. In the United States, LifePort and the XVIVO’s Kidney Assist Transport are the most popular hypothermic perfusion devices, with NMP devices mostly in trials. Combining perfusion with biomarkers such as mitochondrial flavin mononucleotide, neutrophil gelatinase-associated lipocalin, and osteopontin shows promise in assessing kidney viability and predicting post-transplant outcomes, though further research is also needed. Emphasis on repair biomarkers, such as uromodulin and osteopontin, aims to better predict graft outcomes and develop new therapies. While notable advancements have been made in the use of machine perfusion and viability testing for liver transplantation, additional research with larger sample sizes is essential to substantiate these results and enhance kidney transplantation outcomes.
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant Staphylococcus epidermidis Periprosthetic Joint Infection
Cammuso, Melissa Teresa, Cook, Bradley W. M. , Cameron, D. William , Tamayo, Marielou, Peters, Melissa J. , Arnaud, Tia, Lau, S. , Almblad, Henrik , Fournier, Nicolas , LoVetri, Karen, Lightly, Tasia Joy , Chung, Yuen Ming, Roy, Riya , Theriault, Natasha, Theriault, Steven, Suh, Gina A. , Azad, Marisa Ann , Peters, Melissa J , Almblad, Henrik , Suh, Gina A , Azad, Marisa , Ryan, Stephen J. , Arnaud, Tia, Roy, Riya

Mayo Clinic

Viruses | August 14, 2025 | Volume: 17 | Issue: 8 | Pages: 1118

10.3390/v17081118 | PMID 40872831 Get It

We describe the first use of phage therapy in Canada for the treatment of a life-threatening periprosthetic joint infection (PJI), with successful outcome. PJI is a devastating complication of joint replacement surgery, with high morbidity and mortality. Our patient presented with early sepsis from a chronic recalcitrant multidrug-resistant (MDR) Staphylococcus epidermidis hip PJI which had repeatedly failed standard therapy. She had previously undergone 10 operations of the right hip, and only three weeks after completing a prolonged course of daptomycin following her most recent hip revision, she developed a draining sinus tract. Given the high burden of disease, inability to achieve surgical source control, and lack of antibiotic treatment options for long-term suppressive therapy, bacteriophage (phage) therapy was pursued. The patient underwent irrigation and debridement with complex flap reconstruction: intraoperative tissue cultures again yielded MDR S. epidermidis. We developed a novel phage therapy protocol for this patient, with twice daily, intra-articular and intravenous (7 × 109 PFU/dose) phage delivery over a planned 14-day course. Complete healing of the wound with cessation of drainage occurred within one month after treatment. A marked improvement in right hip pain and mobility occurred within three months after treatment. Twelve months following phage treatment, there is normalization of serum inflammatory markers with diminished pain, increased mobility, and no recurrent surgery. Our patient continues to improve and is currently living independently at home, with sustained clinical control of infection.
Guillain-Barré Syndrome Secondary to Snake Bite: A Report of a Rare and Fatal Case
Dhamelia, Parth M. , Mokariya, Dipak R., Anand, Jaspreet Singh, Futela, Pragyat , Baptista, Aleksandra Murawska , Singla, Abhinav , Murawska Baptista, Aleksandra, Anand, Jaspreet Singh , Anand, Jaspreet Singh

Mayo Clinic

American Journal of Case Reports | August 14, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.948917 | PMID 40944946 Get It

Tissue Acquisition Techniques Take Center Stage: Discussion Synopsis of Papanicolaou Society of Cytology Companion Session at International Academy of Cytology Congress, Florence, Italy
Baloch, Zubair , Baskota, Swikrity Upadhyay , Monaco, Sara E. , Faquin, William C , Nassar, Aziza

Mayo Clinic

Diagnostic Cytopathology | August 14, 2025 | Volume: 53 | Issue: 11 | Pages: 521-528

10.1002/dc.70003 | PMID 40808587 Get It

Isolated Sensorineural Hearing Loss as the Sole Manifestation of Granulomatosis with Polyangiitis
Arango, Alejandro , Abril, Andy , Martinez, Alejandro Arango , Mumtaz, Sehreen , Abril, Andy , Mumtaz, Sehreen

Mayo Clinic

American Journal of Case Reports | August 13, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.948700 | PMID 40938809 Get It

Anatomy of the Prostate and Periprostatic Region: A Contemporary Review, From the AJR Special Series on Critical Anatomy
Cheney, Scott M, Yano, Motoyo , Gupta, Amar C, Costa, Daniel Nobrega da , Gupta, Amar C. , Shah, Rajal B.

Mayo Clinic

American Journal of Roentgenology | August 13, 2025 | Volume: 226 | Issue: 5 | Pages: No page available

10.2214/ajr.25.33454 | PMID 40801496 Get It

Visceral adiposity, aortic stiffness, and cardiovascular risk
Harada, Tomonari , Borlaug, Barry A.

Mayo Clinic

European Journal of Preventive Cardiology | August 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwaf516 | PMID 40796340 Get It

A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
Kourelis, Taxiarchis , Ailawadhi, Sikander , Vogl, Dan T. , Gibson, Sarah E. , Sharik, Meaghen E. , Du, Megan T. , Ames, Tyler D. , Yim, Christina Y. , Baeck, Johan , Price, Matthew R. , Jimeno, J. , Chesi, Marta , Jimeno, Jose M , Bergsagel, P. Leif , Ailawadhi, Sikander , Gibson, Sarah E , Bergsagel, P. Leif

Mayo Clinic

Clinical Cancer Research | August 12, 2025 | Volume: 31 | Issue: 21 | Pages: 4518-4528

10.1158/1078-0432.ccr-24-2574 | PMID 40795066 Get It

Abstract Purpose: R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PT-112) is a novel immunogenic cell death–inducing small molecule under phase II development in several cancer types. It inhibits ribosome biogenesis and causes organelle stresses, leading to selective immunogenic cell death in cancer cells. The possibility of PT-112’s pyrophosphate moiety driving high drug concentrations to bone sites of disease has led to an interest in PT-112’s use in multiple myeloma. In this study, we present findings from phase I and in vivo studies for PT-112 in relapsed or refractory multiple myeloma. Experimental Design: PT-112 biodistribution was analyzed in mice via laser ablation inductively coupled plasma mass spectrometry. The activity of PT-112 was assessed in de novo and transplantable Tg(Igkv3-5*-MYC)#Plbe (Vk*MYC) multiple myeloma mouse models as monotherapy or combination therapies. M-spike levels and survival were measured. A phase I dose escalation study of PT-112 monotherapy was conducted using a 3 + 3 design in patients with heavily pretreated relapsed or refractory multiple myeloma with exhausted available therapies. Results: In vivo biodistribution imaging revealed high concentrations in the bone, kidney, lung, skin, and liver. PT-112 was active in Vk*MYC multiple myeloma mouse models, both alone and in combination. Phase I data showed that PT-112 monotherapy was safe and well-tolerated, establishing a recommended phase II dose of 360 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Confirmed responses and other signals of activity were observed. Conclusions: These results suggest a lack of cross-resistance with the standard of care and support the translational value of the Vk*MYC model system. Further clinical investigation of PT-112 is warranted in multiple myeloma.
Alcohol use disorder, but not current alcohol use is associated with falls among people with HIV in care
Dai, Mindy , Chander, Geetanjali , Webel, Allison R. , Whitney, Bridget M. , Christopoulos, Katerina , Moore, Richard D. , Keruly, Jeanne , Bamford, Laura , Cachay, Edward R. , McCaul, Mary E. , Fredericksen, Rob J. , Yendewa, George A. , Saag, Michael S. , Crane, Heidi M. , Cachay, Edward, Delaney, Joseph A. , Mayer, Kenneth Hugh , Christopoulos, Katerina A. , Napravnik, Sonia , Lesko, Catherine R. , Drumright, Lydia N.

Mayo Clinic

AIDS | August 12, 2025 | Volume: 39 | Issue: 14 | Pages: 2094-2102

10.1097/qad.0000000000004317 | PMID 40792693 Get It

Background: Current understanding of associations between alcohol use and falls among people with HIV (PWH) is limited due to few and inconsistent studies. Given the prevalence of heavy episodic alcohol use reported among PWH, this remains an important question. Methods: Alcohol use was measured using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) and self-reported alcohol use treatment and/or diagnosis of alcohol use disorder (collectively AUD) among PWH at eight CFAR Network of Integrated Clinical Systems (CNICS) sites from 2021 to 2024. Falls were self-reported using the components of the Falls Risk for Older People in the Community (FROP-Com) questionnaire. Cross-sectional associations between alcohol use and falls were examined using relative risk models adjusted for age, sex, race/ethnicity, and geographic location. Results: Among 5729 PWH, mean age was 55 years; 42% reported White and 41% reported Black/African American race/ethnicity; and 81% were male. Mean AUDIT-C score was 1.9 (range: 0–12); 27% reported heavy episodic drinking; 22% had AUD; and 22% reported falling in the past year. Reporting at least one fall in the past year was not associated with any measure of current alcohol use. AUD was associated with reporting at least one fall [prevalence ratio = 1.54; 95% confidence interval (CI) 1.39–1.70] and number of falls [one fall: prevalence ratio = 1.27 (95% CI: 1.08–1.50); at least two falls: prevalence ratio = 1.84 (95% CI: 1.58–2.15)]. Conclusion: Among PWH, 22% reported falling, which was associated with AUD, but not current alcohol use, suggesting that a mechanism other than acute intoxication could be responsible. Further longitudinal research is warranted to explore mechanisms for why AUD, but not current alcohol use, is associated with falls.
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel
Mékinian, A. , Georgin‐Lavaille, Sophie, Savic, Sinisa , Koster, Matthew J. , Comont, Thibault , Heilblig, Mael, Aróstegui, Juan I. , Bosco, Annmarie , Cargo, Catherine , Cattaneo, Chiara , Chasset, François , Coelho, Henrique , Ducharme‐Bénard, Stéphanie , Frassi, Micol, Hakobyan, Yervand , Jurcuț, Ciprian , Kirino, Yohei , Kunimoto, Hiroyoshi , Madigan, Lauren M. , Moráis, Sara , Sockel, Katja , Patnaik, Mrinal M. , Regadas, Luísa, Robin, Marie , Rutgers, Abraham , Salvarani, Carlo , Sammel, Anthony M. , Sujobert, Pierre , Tomelleri, Alessandro , Vandergheynst, Frédéric , Vieira, Romana, Viswanatha, David S., Diral, Elisa , Terrier, Benjamin , Fenaux, Pierre, Grayson, Peter C. , Beck, David B. , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological, Mékinian, Arsène , Koster, Matthew J , Bourguiba, Rim , Campochiaro, Corrado , Crisafulli, Francesca , Gurnari, Carmelo , Jamilloux, Yvan , Kirino, Yohei , Marvisi, Chiara , Milchert, Marcin , Rutgers, Abraham , Salvarani, Carlo , Tomelleri, Alessandro , Urbanski, Geoffrey , Terrier, Benjamin , Grayson, Peter C , Beck, David B , Robin, Marie , Savic, Sinisa , Georgin‐Lavialle, Sophie , Ferrada, Marcela A. , Kosmider, Olivier , Calvo, Katherine R. , Campochiaro, Corrado , Faria, Raquel , Franceschini, Franco , Groarke, Emma M , Gurnari, Carmelo , Kulasekararaj, Austin , Mann, H. , Marvisi, Chiara , Milchert, Marcin , Muratore, Francesco , Nakajima, Hideaki , Seebach, Jörg Dieter , Więsik–Szewczyk, Ewa , Patel, Bhavisha A. , Fenaux, Pierre , Diseases, the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological

Mayo Clinic

Arthritis & Rheumatology | August 11, 2025 | Volume: 78 | Issue: 3 | Pages: 509-522

10.1002/art.43287 | PMID 40787890 Get It

Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality. Methods Given the variability in disease presentation and the limited number of studies to date, no clinical documents currently exist to provide guidance to health care providers about the management of VEXAS. To address this gap, we formed an international multidisciplinary panel of VEXAS experts. Results Through formalized meetings and a voting process, the group developed consensus clinical guidance considerations for the management of VEXAS. These considerations offer practical advice on several key topics: (1) clinical features of VEXAS, (2) UBA1 screening methods, (3) the diagnosis of myelodysplastic syndromes (MDSs) in patients with VEXAS, and (4) prognosis and management. The aim is to provide expert guidance on which patients to test, how to test for VEXAS, how to approach MDS in the context of VEXAS, and considerations for management. Conclusion This work marks the first formal international consensus guidance for VEXAS and is intended to be used as a resource for clinicians seeking to understand the disease and its management.